Losartan, an angiotensin II receptor antagonist, is oxidized by hepatic cyt
ochromes P450 to an active carboxylic acid metabolite, E-3174. The aim of t
he present investigation was to study the contribution of CYP2C9 and CYP3A4
in losartan oxidation in vitro and to evaluate the role of CYP2C9 polymorp
hism. Kinetic properties of different genetic CYP2C9 variants were compared
both in a yeast expression system and in 25 different samples of human liv
er microsomes where all known genotypes of CYP2C9 were represented. Microso
mes were incubated with losartan (0.05-50 muM), and the formation of E-3174
was analyzed by high-performance liquid chromatography to estimate V-max,
K-m, and intrinsic clearance for all individual samples. Sulfaphenazole, a
CYP2C9 inhibitor, blocked the formation of E-3174 at low losartan concentra
tions (<1 <mu>M), whereas the inhibitory effect of triacetyloleandomycin, a
CYP3A4 inhibitor, was significant only at high concentrations of losartan
(>25 muM). In comparison to the CYP2C9.1 variant, oxidation of losartan was
significantly reduced in yeast expressing the rare CYP2C9.2 or CYP2C9.3 va
riants. Moreover, the rate of losartan oxidation was lower in liver microso
mes from individuals hetero- or homozygous for the CYP2C9*3 allele, or homo
zygous for the CYP2C9*2 allele. The difference between the common and rare
CYP2C9 variants was mainly explained by a lower V-max, both in yeast and hu
man liver microsomes. In summary, these in vitro results indicate that CYP2
C9 is the major human P450 isoenzyme responsible for losartan oxidation and
that the CYP2C9 genotype contributes to interindividual differences in los
artan oxidation and activation.